Congenital Adrenal Hyperplasia: Innovative Once Daily Dual Release Hydrocortisone Treatment
This is a controlled, open study designed to compare the effects of dual-release hydrocortisone preparations versus conventional glucocorticoid therapy on clinical, anthropometric parameters, metabolic syndrome, hormonal profile, bone status, quality of life, reproductive, sexual and psychological functions and treatment compliance in patients affected by congenital adrenal hyperplasia due to 21 OH deficiency.
• males and females aged \>18 years;
• established diagnosis of adrenal insufficiency in congenital adrenal hyperplasia due to 21-hydroxylase deficiency;
• stably treated with conventional glucocorticoids, available to change their regimen according to random allocation
• written informed consent/assent to participate in the study in compliance with local regulations.